It was a pleasure to speak with Prof. Dr Sven Francque (University of Antwerp, Belgium) about the recent post-hoc analysis of the phase 2 trial of semaglutide in patients with NASH. The analysis was designed to assess whether patient and disease characteristics influenced the effect of the drug on the resolution of NASH.
His abstract entitled ‘Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial’ was presented at EASL ILC 2021, 23-26 June.
Questions
- What did the Phase 2 NN9931-4296 clinical trial teach us about the clinical utility of semaglutide in the treatment of patients with NASH? (0:10)
- Which subgroups were evaluated in the recent post-hoc analysis of the trial data? (0:54)
- What were the findings across the various subgroups, and what are the clinical implications of these findings? (1:30)
- Where do you think semaglutide will likely sit in the treatment paradigm for NASH? (2:12)
Disclosures: Prof. Dr Sven Francque has served as a speaker for AbbVie, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, NovoNordisk and Roche. He has also acted as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, Novo Nordisk and Roche.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
